Contribution of Liraglutide in the Fixed-Ratio Combination of Insulin Degludec and Liraglutide (IDegLira)
The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Insulin degludec/liraglutide (IDegLira) is a novel combination of insulin degludec (IDeg) and liraglutide. This trial investigated the contribution of the liraglutide component of IDegLira versus IDeg alone on efficacy and safety in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS: In a 26-week, double-blind trial, patients with type 2 diabetes (A1C 7.5–10.0% [58–86 mmol/mol]) on basal insulin (20–40 units) and metformin with or without sulfonylurea/glinides were randomized (1:1) to once-daily IDegLira + metformin or IDeg + metformin with titration aiming for fasting plasma glucose between 4 and 5 mmol/L. Maximum allowed doses were 50 dose steps (equal to 50 units IDeg plus 1.8 mg liraglutide) and 50 units for IDeg. The primary end point was change in A1C from baseline. RESULTS: A total of 413 patients were randomized (mean A1C 8.8% [73 mmol/mol]; BMI 33.7 kg/m2). IDeg dose, alone or as part of IDegLira, was equivalent (45 units). A1C decreased by 1.9% (21 mmol/mol) with IDegLira and by 0.9% (10 mmol/mol) with IDeg (estimated treatment difference −1.1% [95% CI −1.3, −0.8], −12 mmol/mol [95% CI −14, −9; P < 0.0001). Mean weight reduction with IDegLira was 2.7 kg vs. no weight change with IDeg, P < 0.0001. Hypoglycemia incidence was comparable (24% for IDegLira vs. 25% for IDeg). Overall adverse events were similar, and incidence of nausea was low in both groups (IDegLira 6.5% vs. IDeg 3.5%). CONCLUSIONS: IDegLira achieved glycemic control superior to that of IDeg at equivalent insulin doses without higher risk of hypoglycemia and with the benefit of weight loss. These findings establish the efficacy and safety of IDegLira and the distinct contribution of the liraglutide component.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In studies of people with type 2 diabetes inadequately controlled on basal insulin or GLP-1 RA, switching to a fi xedratio combination of basal insulin and GLP-1 RA demonstrated signi fi cant improvements in blood glucose levels and achievement of glycemic goals with fewer hypoglycemic events than with basal insulin alone (216 -220).”
Citations
Cites
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919
Self-citationManagement of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetes Care · doi:10.2337/dc12-0413 · Cited by 3,207
Self-citationBuse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503
Self-citationWorld Medical Association Declaration of Helsinki
(2003) · Psychopharmacology · doi:10.1002/047086947x.oth1 · Cited by 1,332
Nauck, M., Frid, A., Hermansen, K., Shah, N. S., Tankova, T., Mitha, I. H., Zdravkovic, M., Düring, M., Matthews, D. R., & for the LEAD-2 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1355 · Cited by 1,129
Inzucchi, S., Bergenstal, R., Buse, J., Diamant, M., Ferrannini, E., Nauck, M., Peters, A., Tsapas, A., Wender, R., & Matthews, D. (2013) · Diabetes Care · doi:10.2337/dc13-er02 · Cited by 805
Self-citationPeyrot, M., Barnett, A. H., Meneghini, L. F., & Schumm‐Draeger, P. ‐. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03605.x · Cited by 655
Buse, J. B., Nauck, M., Forst, T., Sheu, W. H.-H., Shenouda, S. K., Heilmann, C. R., Hoogwerf, B. J., Gao, A., Boardman, M. K., Fineman, M., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61267-7 · Cited by 565
Self-citationBuse, J. B., Bergenstal, R. M., Glass, L. C., Heilmann, C. R., Lewis, M. S., Kwan, A. Y. M., Hoogwerf, B. J., & Rosenstock, J. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-2-201101180-00300 · Cited by 506 · cited 1×
“IDegLira combines the complementary effects of IDeg and liraglutide on glycemic control (10,11,12).”
BackgroundSelf-citationGough, S. C. L., Bode, B., Woo, V., Rodbard, H. W., Linjawi, S., Poulsen, P., Damgaard, L. H., & Buse, J. B. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70174-3 · Cited by 366 · cited 1×
“IDeg in patients with type 2 diabetes inadequately controlled on metformin with or without pioglitazone supports the benefits of IDegLira compared with IDeg as well as liraglutide (21).”
BackgroundSelf-citationInsulin Degludec Versus Insulin Glargine in Insulin-Naive Patients With Type 2 Diabetes
Zinman, B., Philis-Tsimikas, A., Cariou, B., Handelsman, Y., Rodbard, H. W., Johansen, T., Endahl, L., Mathieu, C., & on behalf of the NN1250-3579 (BEGIN Once Long) Trial Investigators (2012) · Diabetes Care · doi:10.2337/dc12-1205 · Cited by 336
Self-citationVijan, S., Hayward, R. A., Ronis, D. L., & Hofer, T. P. (2005) · Journal of General Internal Medicine · doi:10.1111/j.1525-1497.2005.0117.x · Cited by 202
DeVries, J. H., Bain, S. C., Rodbard, H. W., Seufert, J., D’Alessio, D., Thomsen, A. B., Zychma, M., Rosenstock, J., & on behalf of the Liraglutide-Detemir Study Group (2012) · Diabetes Care · doi:10.2337/dc11-1928 · Cited by 159
Self-citationMathieu, C., Rodbard, H. W., Cariou, B., Handelsman, Y., Philis‐Tsimikas, A., Ocampo Francisco, A. M., Rana, A., Zinman, B., & on behalf of the BEGIN: VICTOZA ADD‐ON (NN1250‐3948) study group (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12262 · Cited by 158 · cited 1×
“IDegLira combines the complementary effects of IDeg and liraglutide on glycemic control (10,11,12).”
BackgroundSelf-citationBarriers to insulin initiation and intensification and how to overcome them
Kunt, T., & Snoek, F. J. (2009) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2009.02176.x · Cited by 154
Nauck, M., Frid, A., Hermansen, K., Thomsen, A. B., During, M., Shah, N., Tankova, T., Mitha, I., & Matthews, D. R. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12012 · Cited by 144
Efficacy of Insulin Analogs in Achieving the Hemoglobin A1c Target of <7% in Type 2 Diabetes
Giugliano, D., Maiorino, M. I., Bellastella, G., Chiodini, P., Ceriello, A., & Esposito, K. (2011) · Diabetes Care · doi:10.2337/dc10-1710 · Cited by 128 · cited 1×
“0% [53 mmol/mol]) (1,3,4) and are therefore at”
BackgroundMontanya, E., & Sesti, G. (2009) · Clinical Therapeutics · doi:10.1016/j.clinthera.2009.11.034 · Cited by 126 · cited 1×
“seen in previous trials with liraglutide alone (24).”
MethodForst, T., Michelson, G., Ratter, F., Weber, M. M., Anders, S., Mitry, M., Wilhelm, B., & Pfützner, A. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03589.x · Cited by 75
Type 2 Diabetes Care and Insulin Intensification
Cuddihy, R. M., Philis‐Tsimikas, A., & Nazeri, A. (2010) · The Science of Diabetes Self-Management and Care · doi:10.1177/0145721710388426 · Cited by 69
Pratley, R. E., Nauck, M. A., Bailey, T. S., Montanya, E., Filetti, S., Garber, A. J., Thomsen, A. B., Furber, S., Davies, M. J., & for the 1860-LIRA-DPP-4 Study Group (2012) · Diabetes Care · doi:10.2337/dc11-2113 · Cited by 66
Blak, B. T., Smith, H. T., Hards, M., Maguire, A., & Gimeno, V. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03694.x · Cited by 64 · cited 2×
“0% [53 mmol/mol]) (1,3,4) and are therefore at”
BackgroundInsulin initiation in primary care for patients with type 2 diabetes: 3-Year follow-up study
Dale, J. R., Martin, S., & Gadsby, R. (2010) · Primary care diabetes · doi:10.1016/j.pcd.2010.03.001 · Cited by 57 · cited 1×
“0% [53 mmol/mol]) (1,3,4) and are therefore at”
BackgroundKeating, G. M. (2013) · Drugs · doi:10.1007/s40265-013-0051-1 · Cited by 46
Liraglutide: A Review of its Use in the Management of Type 2 Diabetes Mellitus
Perry, C. M. (2011) · Drugs · doi:10.2165/11208110-000000000-00000 · Cited by 45
Assessing achievement and maintenance of glycemic control by patients initiating basal insulin
Wu, N., Aagren, M., Boulanger, L., Friedman, M., & Wilkey, K. (2012) · Current Medical Research and Opinion · doi:10.1185/03007995.2012.722989 · Cited by 32 · cited 1×
“basal insulin is usually continued even when control is not achieved (1,2).”
BackgroundInsulin Degludec: A Novel Basal Insulin Analogue
Goldman, J. D., Patel, D. K., & Schnee, D. M. (2013) · Annals of Pharmacotherapy · doi:10.1345/aph.1r351 · Cited by 17
Cited by
Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetes Care · doi:10.2337/dci22-0034 · Cited by 2,104
Self-citationDavies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetologia · doi:10.1007/s00125-022-05787-2 · Cited by 1,048
Self-citationUpdate on the treatment of type 2 diabetes mellitus
Marín-Peñalver, J. J., Martín-Timón, I., Sevillano-Collantes, C., & Cañizo-Gómez, F. J. D. (2016) · World Journal of Diabetes · doi:10.4239/wjd.v7.i17.354 · Cited by 647
“In another 26-wk double-blind trial, 413 T2DM patients not controlled with basal insulin and metformin were randomly assigned to exchange basal insulin with insulin degludec or insulin degludec plus liraglutide; all patients continued metformin [192] .”
Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus
Tahrani, A. A., Barnett, A. H., & Bailey, C. J. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.86 · Cited by 398
A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond
Prasad-Reddy, L., & Isaacs, D. (2015) · Drugs in Context · doi:10.7573/dic.212283 · Cited by 365
“superior glycemic control over insulin degludec or liraglutide alone with benefits on weight loss when compared to insulin degludec [79,80].”
Metadata
- Authors
- Buse, J. B., Vilsbøll, T., Thurman, J., Blevins, T. C., Langbakke, I. H., Bøttcher, S. G., & Rodbard, H. W.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- University of Copenhagen (DK)
- SSM Health Care (US)
- Texas Diabetes & Endocrinology (US)
- Novo Nordisk (Denmark) (DK)
- Endocrine and Metabolic Consultants, Clinical Research, Rockville, MD
- Corresponding author
- Buse, John B.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2014-10-10
- Volume
- 37
- Issue
- 11
- Pages
- 2926-2933
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2126862523
- Cited by
- 259
- References
- 27
- Citations by year
- 2026: 10 · 2025: 13 · 2024: 10 · 2023: 11 · 2022: 14 · 2021: 14 · 2020: 16 · 2019: 30 · 2018: 39 · 2017: 41 · 2016: 30 · 2015: 26 · 2014: 4
- FWCI
- 26.94
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Novo Nordisk Fonden (NNF12OC1015904)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- insulin degludec, liraglutide, IDegLira, type 2 diabetes, glycemic control, HbA1c, weight loss, hypoglycemia, basal insulin, metformin, GLP-1 receptor agonists, nausea, fixed-dose combination
- MeSH terms
- Liraglutide, Aged, Blood Glucose, Diabetes Mellitus, Type 2, Double-Blind Method, Drug Combinations, Drug Therapy, Combination, Female, Humans, Hypoglycemia, Hypoglycemic Agents, Male, Metformin, Middle Aged, Sulfonylurea Compounds, Weight Loss, Treatment Outcome, Insulin, Long-Acting, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.